Rohto Pharmaceutical (4527) Q4 2026 earnings summary

Executive summary

• Achieved record-high net sales of ¥343.7 billion (+11.4% YoY) and operating income of ¥41.1 billion (+7.5% YoY), outperforming full-year forecasts.

• Profit attributable to owners of parent rose 11.0% YoY to ¥34.2 billion, driven by higher non-operating income.

• Growth was driven by strong domestic and overseas sales, including contributions from newly consolidated subsidiaries in Asia and Europe.

• Annual dividend increased to ¥46, marking 22 consecutive years of growth, with a forecast of ¥50 for FY2027.

• Finalized accounting for recent business combinations impacted goodwill and intangible assets, with significant revisions reflected in comparative figures.

Financial highlights

• EBITDA reached ¥58.5 billion (+13.5% YoY), with an EBITDA margin of 17.0%.

• Ordinary income rose 20.8% YoY to ¥47.97 billion.

• Comprehensive income surged 41.3% to ¥48.8 billion.

• Gross profit increased to ¥192.7 billion (+10.5% YoY), despite a higher COGS ratio.

• Net assets rose to ¥320.2 billion, with an equity-to-asset ratio of 62.1%.

Outlook and guidance

• FY2027 forecast: sales ¥369.5 billion (+7.5% YoY), operating income ¥43.8 billion (+6.5% YoY), profit attributable to owners of parent ¥34.5 billion (+0.7% YoY).

• Double-digit sales growth expected in Asia and Europe; depreciation of yen anticipated.

• Annual dividend planned to increase to ¥50, targeting 23 consecutive years of growth.

• Continued moderate recovery in Japan expected, but overseas uncertainties and geopolitical risks remain.